Molecular Imaging as a critical tool in discovery of the basis of tumour heterogeneity and developing novel therapies to overcome therapeutic resistance

分子成像是发现肿瘤异质性基础和开发克服治疗耐药性的新疗法的关键工具

• 批准号: nhmrc : GNT1108050
• 负责人: Prof Rodney Hicks
• 金额: $ 46.8万
• 依托单位国家: 澳大利亚
• 项目类别: Practitioner Fellowships
• 财政年份: 2016
• 资助国家: 澳大利亚
• 起止时间: 2016-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/molecular-imaging-critical-therapeutic-resistance/1346620
• 关键词: Molecular; Imaging; critical; tool; discovery

Determining treatment options for cancer currently relies on the size and extent of tumour deposits on imaging, combined with a biopsy. However, this approach fails to recognise the ability of tumours to evolve components that are, or become, resistant to treatment. My laboratory uses advanced molecular imaging, targeted biopsies, animal models and genetic analysis to detect and understand the basis of such resistance and thereby develop new, targeted treatments to improve patient outcomes.

目前，确定癌症的治疗方案依赖于成像上肿瘤沉积的大小和范围，并结合活检。然而，这种方法未能认识到肿瘤进化出抗药性成分的能力。我的实验室使用先进的分子成像、靶向活检、动物模型和遗传分析来检测和了解这种耐药性的基础，从而开发新的、有针对性的治疗方法来改善患者的预后。